B-intervention	0	8	Sentinel
I-intervention	9	14	lymph
I-intervention	15	19	node
I-intervention	20	26	biopsy
O	27	29	in
O	30	38	patients
O	39	43	with
O	44	54	multifocal
O	55	61	breast
O	62	68	cancer
O	68	69	.

O	70	80	Multifocal
O	81	83	or
O	84	96	multicentric
O	97	103	breast
O	104	110	cancer
O	111	114	has
O	115	119	been
O	120	129	suggested
O	130	132	as
O	133	134	a
O	135	151	contraindication
O	152	155	for
O	156	164	sentinel
O	165	169	node
O	170	176	biopsy
O	177	178	(
O	178	181	SNB
O	181	182	)
O	182	183	.

O	184	191	However
O	191	192	,
O	193	199	recent
O	200	207	studies
O	208	212	have
O	213	225	demonstrated
O	226	230	that
O	231	234	all
O	235	244	quadrants
O	245	247	of
O	248	251	the
O	252	258	breast
O	259	264	drain
O	265	272	through
O	273	279	common
O	280	288	afferent
O	289	297	channels
O	298	300	to
O	301	302	a
O	303	309	common
O	310	318	axillary
O	319	327	sentinel
O	328	332	node
O	332	333	.

O	334	338	This
O	339	345	should
O	346	350	mean
O	351	355	that
O	356	359	the
O	360	368	presence
O	369	371	of
O	372	382	multifocal
O	383	389	tumour
O	390	396	should
O	397	400	not
O	401	407	affect
O	408	411	the
O	412	421	lymphatic
O	422	430	drainage
O	430	431	.

O	432	435	The
O	436	443	purpose
O	444	446	of
O	447	451	this
O	452	457	study
O	458	461	was
O	462	464	to
O	465	473	evaluate
O	474	477	the
O	478	489	feasibility
O	490	493	and
O	494	502	accuracy
O	503	505	of
O	506	509	SNB
O	510	512	in
O	513	521	patients
O	522	526	with
O	527	537	multifocal
O	538	544	breast
O	545	551	cancer
O	552	557	using
O	558	559	a
O	560	572	peritumoural
O	573	582	injection
O	583	592	technique
O	593	596	for
O	597	605	sentinel
O	606	611	lymph
O	612	616	node
O	617	618	(
O	618	620	SN
O	620	621	)
O	622	629	mapping
O	629	630	.

O	631	633	In
O	634	637	the
O	638	645	ALMANAC
O	646	657	multicentre
O	658	663	trial
O	664	674	validation
O	675	680	phase
O	680	681	,
O	682	684	we
O	685	689	took
O	690	693	SNB
O	694	701	samples
O	702	706	from
B-total-participants	707	710	842
B-eligibility	711	719	patients
I-eligibility	720	724	with
I-eligibility	725	729	node
I-eligibility	730	738	negative
I-eligibility	738	739	,
I-eligibility	740	748	invasive
I-eligibility	749	755	breast
I-eligibility	756	762	cancer
O	763	767	with
O	768	771	use
O	772	774	of
O	775	776	a
O	777	781	blue
O	782	785	dye
O	786	789	and
O	790	803	radiolabelled
O	804	811	colloid
O	812	819	mapping
O	820	829	technique
O	830	832	at
O	833	836	the
O	837	849	peritumoural
O	850	859	injection
O	860	864	site
O	864	865	.

O	866	869	All
O	870	878	patients
O	879	888	underwent
O	889	897	standard
O	898	906	axillary
O	907	916	treatment
O	917	922	after
O	923	926	SNB
O	926	927	.

O	928	935	Seventy
O	935	936	-
O	936	940	five
O	941	943	of
O	944	947	the
O	948	951	842
O	952	960	patients
O	961	964	had
O	965	975	multifocal
O	976	983	lesions
O	984	986	on
O	987	992	final
O	993	1008	histopathologic
O	1009	1020	examination
O	1020	1021	.

O	1022	1025	The
O	1026	1035	following
O	1036	1044	analysis
O	1045	1047	is
O	1048	1055	focused
O	1056	1058	on
O	1059	1067	patients
O	1068	1072	with
O	1073	1083	multifocal
O	1084	1091	lesions
O	1091	1092	.

O	1093	1094	A
O	1095	1099	mean
O	1100	1106	number
O	1107	1109	of
O	1110	1111	2
O	1111	1112	.
O	1112	1113	4
B-outcome	1114	1117	SNs
O	1118	1122	were
O	1123	1133	identified
O	1134	1136	in
B-iv-bin-abs	1137	1139	71
O	1140	1142	of
B-intervention-participants	1143	1145	75
O	1146	1154	patients
O	1155	1156	(
O	1156	1170	identification
O	1171	1175	rate
O	1175	1176	:
B-iv-bin-percent	1177	1179	94
I-iv-bin-percent	1179	1180	.
I-iv-bin-percent	1180	1181	7
I-iv-bin-percent	1181	1182	%
O	1182	1183	)
O	1183	1184	.

B-iv-bin-abs	1185	1191	Thirty
I-iv-bin-abs	1191	1192	-
I-iv-bin-abs	1192	1195	one
O	1196	1204	patients
O	1205	1208	had
O	1209	1210	a
B-outcome	1211	1219	positive
I-outcome	1220	1222	SN
O	1222	1223	,
B-iv-bin-abs	1224	1226	40
O	1227	1228	a
B-outcome	1229	1237	negative
I-outcome	1238	1240	SN
O	1240	1241	.

O	1242	1250	Standard
O	1251	1259	axillary
O	1260	1269	treatment
B-outcome	1270	1279	confirmed
I-outcome	1280	1283	the
I-outcome	1284	1286	SN
I-outcome	1287	1289	to
I-outcome	1290	1292	be
I-outcome	1293	1301	negative
O	1302	1304	in
B-iv-bin-abs	1305	1307	37
O	1308	1310	of
B-intervention-participants	1311	1313	40
O	1314	1322	patients
O	1322	1323	,
O	1324	1331	whereas
B-iv-bin-abs	1332	1337	three
O	1338	1346	patients
O	1347	1355	revealed
B-outcome	1356	1364	positive
I-outcome	1365	1368	non
I-outcome	1368	1369	-
I-outcome	1369	1377	sentinel
I-outcome	1378	1383	lymph
I-outcome	1384	1389	nodes
O	1390	1391	(
O	1391	1396	false
O	1396	1397	-
O	1397	1405	negative
O	1406	1410	rate
O	1410	1411	:
O	1412	1413	8
O	1413	1414	.
O	1414	1415	8
O	1415	1416	%
O	1416	1417	)
O	1417	1418	.

O	1419	1426	Overall
O	1427	1429	SN
O	1430	1436	biopsy
B-outcome	1437	1447	accurately
I-outcome	1448	1457	predicted
I-outcome	1458	1466	axillary
I-outcome	1467	1472	lymph
I-outcome	1473	1477	node
I-outcome	1478	1484	status
O	1485	1487	in
B-iv-bin-abs	1488	1490	68
O	1491	1493	of
B-intervention-participants	1494	1496	71
O	1497	1505	patients
O	1506	1507	(
B-iv-bin-percent	1507	1509	95
I-iv-bin-percent	1509	1510	.
I-iv-bin-percent	1510	1511	8
I-iv-bin-percent	1511	1512	%
O	1512	1513	)
O	1513	1514	.

O	1515	1518	SNB
O	1519	1529	accurately
O	1530	1536	staged
O	1537	1540	the
O	1541	1547	axilla
O	1548	1550	in
O	1551	1561	multifocal
O	1562	1568	breast
O	1569	1575	cancer
O	1576	1579	and
O	1580	1583	may
O	1584	1590	become
O	1591	1593	an
O	1594	1605	alternative
O	1606	1608	to
O	1609	1617	complete
O	1618	1626	axillary
O	1627	1632	lymph
O	1633	1637	node
O	1638	1648	dissection
O	1649	1651	in
O	1652	1656	node
O	1657	1665	negative
O	1666	1674	patients
O	1675	1679	with
O	1680	1690	multifocal
O	1691	1697	breast
O	1698	1704	cancer
O	1704	1705	.
